The global antipyretic drug market is anticipated to grow at a CAGR of 2.2% during the forecast period (2023-2030). the growth of the global antipyretic drug market is driven by growing number of bacterial and viral infections globally and also medical treatment costs has seen dramatic growth globally. In january 2023, hyloris announces commercial partnership for maxigesic iv in 9 european countries. It is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion, thereby reducing both pain and inflammation. Since the pandemic, healthcare has been the greatest driver to our high inflation rates. Healthcare is a basic need where demand is driven by disease growth, which is influenced by new kind of viruses and diseases approaching the world. However, lack of reliability on antipyretic drug in backward and underdeveloped countries considerably hampers the growth of antipyretic drug market. In January 2023, France faced Supply problems with amoxicillin and paracetamol have highlighted reliance on chemicals from China and India. In particular, paracetamol and the common penicillin antibiotic amoxicillin, especially in child doses, are becoming increasingly hard to obtain in pharmacies.
Browse the full report description of “Antipyretic Drug Market Size, Share & Trends Analysis Report by Type (Paracetamol, Ibuprofen, Aspirin, NSAID and Others), by Sales Type (Prescription and Over the Counter (OTC)), by Sales Channels (Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies, and Others) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/antipyretic-drug-market
Medical integrates advanced healthcare, treatment, and operation planning, using technology to streamline the product life cycle, in turn, and targeting higher efficiency. For instance, in September 2022, Health officials warned that the start of the autumn Covid wave had begun earlier this week, with early signs of rising cases. The UK Health Security Agency has also warned of a 'twindemic' in the coming months, with flu expected to rise as well. Also Ibuprofen and paracetamol are facing a shortage in China at the moment, they are high in demand. India, is ready to step up exports of fever medicines to China as it reels from a spike in COVID-19 cases, the chairperson of an Indian drug export body.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Sale Type
o By Sales Channels
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Johnson and Johnson (J&J), Cipla Ltd., and others.
Key Questions Addressed by the Report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Antipyretic Drug Market Report Segment
By Type
By Sales Type
By Sales Channels
Global Antipyretic Drug Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antipyretic-drug-market